Shorter Fasting After Endoscopic Submucosal Dissection Feasible

This article originally appeared here.
Share this content:
Shorter Fasting After Endoscopic Submucosal Dissection Feasible
Shorter Fasting After Endoscopic Submucosal Dissection Feasible

WEDNESDAY, June 28, 2017 (HealthDay News) -- For patients undergoing endoscopic submucosal dissection (ESD), a short fasting period after the procedure is associated with shorter hospital stay and greater patient satisfaction, with no impact on discomfort or bleeding, according to a study published online June 23 in the Journal of Digestive Diseases.

Kwang Hoon Oh, M.D., from Ulsan University College of Medicine in Gangneung, South Korea, and colleagues enrolled patients into a short and long fasting group. In the short fasting group, patients fasted until the next day after ESD, while patients fasted until two days after ESD in the long fasting group. Immediately prior to restarting diet, a second-look endoscopy was performed. Data were analyzed from 101 patients.

The researchers found that reports of epigastric pain, heartburn, regurgitation, nausea, and vomiting after diet did not differ between the groups. Upon second-look endoscopy, both groups had similar rates of hemostasis (26 versus 31.4 percent; P = 0.551) and bleeding rates (4 versus 0 percent; P = 0.149). The short fasting group had significantly shorter duration of hospital stay than the long fasting group (4.12 versus 5.11 days; P < 0.001), as well as greater patient satisfaction (P = 0.003).

"The short fasting period does not cause discomfort related to ESD nor does it influence post ESD bleeding," the authors write. "Moreover, the short fasting protocol results in shorter hospital stays and greater patient satisfaction."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »